Accepted for Publication: January 2, 2015.
Study concept and design: Latov.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Latov.
Critical revision of the manuscript for important intellectual content: Kumar, Vo, Chin, Carey, Langsdorf, Feuer.
Statistical analysis: Latov, Kumar.
Administrative, technical, or material support: Vo, Chin, Carey, Feuer.
Study supervision: Latov, Feuer.
Conflict of Interest Disclosures: Dr Latov has served as a consultant to Merck, Baxter, CSL Behring, Pfizer, Xenoport, Novartis, and Oncogenex; owns stock in Therapath; is the beneficiary of a research grant from Grifols to Cornell University; and receives book royalties from the American Academy of Neurology. Dr Vo is the beneficiary of a research grant from Grifols to Cornell University. No other disclosures were reported.